Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 13Zollinger-Ellison Syndrome 2Vipoma 2Somatostatinoma 2Pheochromocytoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Carcinoma, Medullary 2Carcinoid Tumor 2Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lung Neoplasms 1Insulinoma 1Glucagonoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Gastrinoma 1Frailty 1Extrapancreatic Neuroendocrine Tumor 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Frailty × Temozolomide × NET × Clear all
NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting
46 enrolled
EndocrineNET

Frailty, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡